CooperVision will share new data and analysis demonstrating the performance and efficacy of its innovative MiSight^® 1 day contact lens during the 2022 Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver from May 1-4.

“The increasing severity and prevalence of myopia progression in children is one of the greatest healthcare issues today, with consequences that will last for generations,” said Paul Chamberlain, BSc (Hons), Director of Research Programs for CooperVision. “Our extensive scientific and commercial innovations have made it easier for eye care professionals to address this challenge and incorporate myopia management as the standard of care. The works we are presenting at ARVO build further confidence in MiSight^® 1 day contact lenses^* as a preferred approach.”  

Dual Focus Contact Lenses Induce Myopic Defocus in Children During Near Viewing (Meyer D, et al) presents evidence that myopia control using MiSight^® 1 day contact lenses in age-appropriate children is achieved through added myopic defocus, validating prior hypotheses. The study also quantified the myopic defocus dose delivered to children in two ways: by diopters and by the proportion of light focused in front of the retina. This work was conducted with the Indiana University School of Optometry.

Prior Myopia Control Effects Retained Upon Cessation of Dual-Focus Soft Contact Lens Wear (Hammond D, et al) offers further in-depth analysis of the seven-year MiSight^® 1 day clinical trial, which is the longest-running soft contact lens study among children. The twelve months following treatment cessation, mean axial elongation data indicated no evidence of rebound effect, signifying the myopia control gains were retained.

This latest work provides a deeper dive into the year seven data. These results indicate that treatment effects are retained regardless of when treatment ceased at any age between 14 to 18. The investigators conclude that starting MiSight^® 1 day at a younger age* and continuing throughout teenage years reduces time during which untreated eye growth can occur.

Click HERE for the full press release.

The 50^th edition of MIDO came to an end May 1 amid enthusiasm and optimism. The appointment for all industry professionals is for next year, February 4-6, 2023, at Fiera Milano Rho.

Plenty of innovations and a variety of experiences were offered to participants eager to experience emotions and meet each other in-person, at an engaging event that brings fashion back to the forefront and relaunches the eyewear industry. From the opening event world premiere of the previously unreleased music composition by Maestro Ennio Morricone “Infinite Visioni”, to the performance by Dargen D’Amico and the celebration of the stars of the show and of the industry with the Bestore and Stand Up For Green awards.

“The bottom line for this edition is undoubtedly positive because the 22,000 visitors to MIDO 2022 were of high quality and driven by a willingness to buy, despite the challenging times, overcoming the adversities of the difficult moment we are experiencing – said Giovanni Vitaloni, President of MIDO. We confirmed our ability to be benchmark for the sector, strengthening MIDO’s role in the creation of business and ideas. We have had excellent feedback from exhibitors and visitors alike on the activity experienced here: this is a fresh start for the industry. Exhibitions should be in-person events…” concluded Vitaloni.

The over 660 exhibitors from 45 countries across 5 pavilions and 8 exhibition areas met visitors from over 50 countries: Europe, United States, Israel, Brazil, India, Tunisia, Iran, South Africa and United Arab Emirates.

Equally significant was the presence of online participants connected to the B2B platform, designed to engage in the show those who – from all over the world – were unable to attend the live event. The wonder of MIDO was also broadcast live on MIDOTV, which this year produced 77 videos broadcast live on YouTube, with a total of 350,000 views.

SEE YOU IN 2023, ON FEBRUARY 4-6

Click HERE for the full press release.